Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Robert Bonakdar MD, FAAFP, FACN
Robert Bonakdar MD, FAAFP, FACN Advisory Board
Tricia Elliott MD, FAAFP
Tricia C. Elliott MD, FAAFP Associate Editor
Irene Hamrick MD, FAAFP, AGSF, CMD
Irene Hamrick MD, FAAFP, AGSF, CMD Advisory Board
See All Experts
story of the week
Published in Primary Care and
1 other channel

Journal Scan / Research · July 10, 2024

Long-Term Kidney Outcomes of Semaglutide in Obesity and Cardiovascular Disease

Nature

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Peter Lin MD, CCFP

Giselle Suero-Abreu MD, PhD, MSc

Nature
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Nature 2024 May 25;[EPub Ahead of Print], HM Colhoun, I Lingvay, PM Brown, J Deanfield, K Brown-Frandsen, SE Kahn, J Plutzky, K Node, A Parkhomenko, L Rydén, JPH Wilding, JFE Mann, KR Tuttle, T Idorn, N Rathor, AM Lincoff

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated